A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading...

Source: Arthritis Research and Therapy - October 16, 2023 Category: Rheumatology Authors: Wolfgang A. Schmidt, Bhaskar Dasgupta, Jennifer Sloane, Angeliki Giannelou, Yuqing Xu, Sebastian H. Unizony, Sarah L. Mackie, Miguel A. Gonzalez-Gay, Robert Spiera, Kenneth J. Warrington, Peter M. Villiger, Michael C. Nivens, Bolanle Akinlade, Yong Lin, F Tags: Research Source Type: research